rs2070744 — NOS3 T-786C promoter
NOS3 expression - controls how much eNOS enzyme is produced for nitric oxide synthesis
Details
- Gene
- NOS3
- Chromosome
- 7
- Risk allele
- C
- Consequence
- Regulatory
- Inheritance
- Codominant
- Clinical
- Risk Factor
- Evidence
- Strong
- Chip coverage
- v3 v4 v5
Population Frequency
Ancestry Frequencies
Related SNPs
Category
Methylation & DetoxNOS3 T-786C Promoter - Controlling Enzyme Production
While rs1799983 affects the structure of the eNOS enzyme, the T-786C 11 The -786 means 786 base pairs upstream of the gene's start; T-to-C is the nucleotide change promoter variant (rs2070744) controls how much enzyme is produced in the first place. This variant sits in the promoter region of the NOS3 gene, which is the DNA sequence that regulates gene transcription.
The Mechanism
The C allele at position -786 reduces NOS3 gene transcription by altering transcription factor binding. 22 Transcription factors are proteins that bind to specific DNA sequences to turn genes on or off A protein called replication protein A1 (RPA1) binds to the C allele more strongly, acting as a transcriptional repressor. The result is less eNOS mRNA, less protein, and ultimately less nitric oxide production capacity in your blood vessel walls. Studies have shown that the CC genotype reduces promoter activity by 30-40% compared to TT.
Compounding Effects
This promoter variant is particularly significant when combined with the Glu298Asp structural variant (rs1799983). Having both means you produce less enzyme (due to the promoter variant) AND the enzyme you do produce is less stable (due to the structural variant). 33 This is analogous to a factory that both makes fewer units and has a higher defect rate on the ones it does make This compound effect can meaningfully reduce your nitric oxide availability.
Evidence and Clinical Relevance
Nakayama et al.44 Nakayama et al.
Nakayama M et al. T-786C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation, 1999
found that the mutant allele was the most predictive independent risk factor for
coronary spasm in a study of 174 patients and 161 controls. The CC genotype is
associated with increased risk of coronary artery spasm, hypertension, and
endothelial dysfunction in multiple populations.
Supporting Nitric Oxide Production
The strategies for supporting NO production are the same regardless of which NOS3 variant you carry: regular aerobic exercise (the most potent natural eNOS stimulator), dietary nitrates from vegetables (beets, spinach, arugula), adequate antioxidant intake to prevent eNOS uncoupling, and avoiding smoking, which directly damages endothelial function.
Nutrient Interactions
Genotype Interpretations
What each possible genotype means for this variant:
Normal NOS3 expression
Your NOS3 gene is expressed at normal levels, producing adequate eNOS enzyme for nitric oxide synthesis. About 40% of Europeans share this genotype.
Reduced NOS3 expression
You carry one promoter variant reducing NOS3 expression by approximately 15-20%. Less enzyme means less nitric oxide production capacity. About 44% of Europeans share this genotype.
Significantly reduced NOS3 expression
Two promoter variants reduce NOS3 expression by 30-40%. Combined with the structural variant rs1799983, this compounds the effect on nitric oxide production. About 16% of Europeans share this genotype.
Key References
Nakayama et al. identified T-786C mutation as significantly associated with coronary spasm in 174 patients vs 161 controls
Casas et al. meta-analysis including T-786C among three NOS3 polymorphisms and ischemic heart disease
NOS3 rs1799983 and rs2070744 polymorphisms and their association with chronic kidney disease and coronary heart disease